ArticleNature nanotechnology2024
An artificial metabzyme for tumour-cell-specific metabolic therapy.
Abstract read
In one paragraph
Article in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Can nanozymes make the leap to the clinic? Advances, hurdles, and prospects.Trends in biotechnology · 2026Review
- Fe-MOF@Quercetin complex with light-controlled redox modulation for tumor wound repair.Materials today. Bio · 2026Article
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Engineering-Modulated Molybdenum Enzymes Strategy for Tumor-Specific Metabolic-Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ion sequential therapy aligned with pathological changes enhances cardiac function after myocardial infarction.Cell reports. Medicine · 2026Article
- Light-driven thermotropic hydrogel with nanomodulator enables lipid intervention and cavity delivery for postsurgical tumor therapy.Cell reports. Medicine · 2026Article
- An inflammation-modulating ferroptotic nanoplatform for immune-compatible cancer therapy.Journal of nanobiotechnology · 2026Article
- Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.Journal of nanobiotechnology · 2026Article
- Serum uric acid and its metabolism-a vital factor in the inflammatory transformation of cancer.Journal of advanced research · 2026Review
- Bi-Polar Bioenergetic Intervention via a Pathology Self-Adaptive Single-Atom Nanocatalyst for Diabetic Tumor Postoperative Management.Nano-micro letters · 2026Article
- A programmable nanoreactor for photothermal immunotherapy via NIR-II triggered enzyme-catalyzed immunogenic tumor microenvironment remodeling.Asian journal of pharmaceutical sciences · 2026Article
- Advances in artificial metabzymes for macrophage polarization in tumor metabolic immunotherapy.Materials today. Bio · 2026Article
- NIR-II imaging-guided nanoplatform for synergistic mitochondria-targeted pyroptosis and macrophage reprogramming immunotherapy.Materials today. Bio · 2026Article
- Atomically Precise Clusterzymes: A Programmable Optoelectronic Platform for Neuroscience.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Multifunctional nanoplatforms for tumor microenvironment remodeling: Toward precision and intelligent cancer therapy.Materials today. Bio · 2025Review
- Spatiotemporal-adaptive nanotherapeutics promote post-injury regeneration in ageing through metabolic modulation.Nature nanotechnology · 2025Article
- Purine metabolism: a pan-cancer metabolic dysregulation across circulation and tissues.Molecular cancer · 2025Article
- Nanotechnology for immuno-oncology.Nature cancer · 2025Review
- Ferumoxytol promotes haematopoietic stem cell post-injury regeneration as a reactive oxygen species scavenger.Nature nanotechnology · 2025Article
- Self-contained G-quadruplex/hemin DNAzyme: a superior ready-made catalyst for in situ imaging analysis.Nucleic acids research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Xi Hu *Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-2533-4408
Bo Zhang *Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-1579-3707
Miao Zhang *Institute of Pharmaceutics, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, the First Affiliated Hospital, Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumour of Zhejiang Province, Zhejiang University, Hangzhou, China.
Wenshi Liang *Institute of Pharmaceutics, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, the First Affiliated Hospital, Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumour of Zhejiang Province, Zhejiang University, Hangzhou, China.
Bangzhen HongSchool of Pharmacy, Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Anhui University of Chinese Medicine, Hefei, China.
Zhiyuan MaInstitute of Pharmaceutics, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, the First Affiliated Hospital, Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumour of Zhejiang Province, Zhejiang University, Hangzhou, China.
Jianpeng ShengInstitute of Pharmaceutics, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, the First Affiliated Hospital, Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumour of Zhejiang Province, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-5535-5541
Tianqi LiuSchool of Pharmacy, Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Anhui University of Chinese Medicine, Hefei, China.
Shengfei YangInstitute of Pharmaceutics, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, the First Affiliated Hospital, Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumour of Zhejiang Province, Zhejiang University, Hangzhou, China.
Zeyu LiangFrontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.
Jichao ZhangShanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0002-7400-6726
Chunhai FanFrontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-7171-7338
Fangyuan LiSongjiang Hospital and Songjiang Research Institute, Shanghai Key Laboratory of Emotions and Affective Disorders, Shanghai Jiao Tong University School of Medicine, Shanghai, China. lfy@shsmu.edu.cn.ORCID http://orcid.org/0000-0002-8086-7362
Daishun LingFrontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China. dsling@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-9977-0237
Funding
National Natural Science Foundation of China (National Science Foundation of China) 32000985National Natural Science Foundation of China (National Science Foundation of China) 32071374Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LQ21H300003Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LR22C100001
Abstract
Metabolic dysregulation constitutes a pivotal feature of cancer progression. Enzymes with multiple metal active sites play a major role in this process. Here we report the first metabolic-enzyme-like FeMoO
Indexed as
NeoplasmsAnimalsCell Line, TumorHumansMetabolomicsMiceUric AcidXanthineXanthine DehydrogenaseUric AcidXanthineXanthine Dehydrogenase
Identifiers
PMID
39103450What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.